Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life
- 1 January 2017
- journal article
- research article
- Published by Elsevier in International Journal of Cardiology
- Vol. 227, 261-266
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Hemorrhagic Complications in Emergency Department Patients Who Are Receiving Dabigatran Compared With WarfarinAnnals of Emergency Medicine, 2013
- Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or DabigatranStroke, 2012
- Bleeding Risk with Dabigatran in the Frail ElderlyNew England Journal of Medicine, 2012
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Incidence, clinical impact and risk of bleeding during oral anticoagulation therapyWorld Journal of Cardiology, 2011
- Guidelines for the management of atrial fibrillationEP Europace, 2010
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- Rivaroxaban – an oral, direct Factor Xa inhibitor – lessons from a broad clinical study programmeEuropean Journal of Haematology, 2009
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005